GSI (Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg)
Generic Name: emtricitabine/rilpivirine/tenofovir
Pill imprint GSI has been identified as Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg.
Complera is used in the treatment of hiv infection and belongs to the drug class antiviral combinations. There is no proven risk in humans during pregnancy. Complera emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- emtricitabine 200 mg, rilpivirine 25 mg and tenofovir disoproxil fumarate 300 mg
- Prescription only
- Drug Class:
- Antiviral combinations
- Pregnancy Category:
- B - No proven risk in humans
- CSA Schedule:
- Not a controlled drug
- Gilead Sciences, Inc.
More about Complera (emtricitabine / rilpivirine / tenofovir)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- En Español
- 56 Reviews – Add your own review/rating
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.